Dry Eye Disease
Conditions
Keywords
dry eye disease; post refractive surgery; blepharospasm; exosomes; mesenchymal stem cell; pluripotent stem cell
Brief summary
The purpose of this study is to evaluate the preliminary safety and effectiveness of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops in the treatment of dry eye diseases post refractive surgery and associated with blepharospasm
Detailed description
Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by instability of the tear film and the prevalence has been estimated to reach 20%-40%. Especially, dry eye symptoms are common complaints of patients with blepharospasm or refractive surgery history, seriously affecting their quality of life. There are many conventional therapies for DED which include ocular lubricants, oral essential fatty acid supplementation, lid hygiene and warm compresses, punctal occlusion, various treatments to obstructed meibomian glands, topical antibiotics, topical corticosteroids, topical secretagogues, topical non-glucocorticoid immunomodulatory drugs and scleral contact lenses. However, the overall efficacy is still unsatisfactory with apparent side effects, long periods of treatment, and high-costs. Mesenchymal stem cell-derived exosomes (MSC-Exo) are 30-150nm microvesicles secreted by mesenchymal stem cells (MSCs), which can mediate the therapeutic efficacy of mesenchymal stem cells by the encapsulated proteins, miRNAs and other bioactive substances, and showed potential in the treatment of various diseases. This study aims to evaluate the preliminary safety and effectiveness of PSC-MSC-Exo in the treatment of dry eye diseases post refractive surgery and associated with blepharospasm. This is an open-label, single-arm, before-after study with 12 subjects with dry eye diseases and the history of refractive surgery or blepharospasm. There are 5 visits over the course of 12 weeks. Visit 1: Week-1 Visit 2: Week-2 Visit 3: Week-4 Visit 4: Week-8 Visit 5: Week-12
Interventions
DRUGPluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops
Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
Sponsors
Zhejiang University
Hangzhou yuansheng biotechnology Co., Ltd
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* clinical diagnosis of apparent dry eye symptoms by ophthalmologists. * patients experience dry eye symptoms with a definitive history of FS-LASIK or SMILE surgery, or blepharospasm, and previous application of artificial tears for more than 3 months could not relieve the dry eye symptoms. * have the following symptoms in at least one eye: dryness, burning sensation, foreign body sensation, discomfort in the ocular surface or visual fatigue; * tear secretion test (Schirmer's Test) of either eye ≤ 10 mm / 5 min; * the corneal fluorescein staining score (FLCs) was more than 3 and less than 6. * Tear break up time (TBUT) is less than 10 seconds.
Exclusion criteria
* Those who are allergic to any component of the drug in this study; * Pregnant or nursing women; * Patients with active fungal, bacterial or viral keratitis or conjunctivitis; * have serious heart, lung, liver or kidney diseases; * Other incurable ocular diseases before the study; such as glaucoma, uveitis, retinitis pigmentosa. * Wearing contact lenses and unwilling to take off in the study; * Performed ocular surgery (including cataract surgery) in recent three months; * Enrolled in other interventional clinical studies at the same time; * Application of eye drops that might affect the clinical study in the past 24 hours; * Unable to complete the study according to the investigators' requirements; * Application of eye drops other than artificial tears. * Application of systemic medication known to reduce tear production, such as anti-anxiety drugs, antipsychotics and steroids. * Eyelids or eyelashes anomaly. * Serious systemic diseases. * Refused to sign the informed consent form to participate in the experiment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Ocular Surface Disease Index (OSDI) | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | The OSDI questionnaire contains 12 questions to measure dry eye symptoms. OSDI scores range from 0 to 100. The lower the score, the more alleviation of dry eye symptoms. Compared with the baseline, a reduction of more than 10 points indicates improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tear Film Break-up Time | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | Time required for dry spots to appear on the surface of the eye after blinking was measured in seconds. A positive change from baseline indicates improvement in each eye. |
| Ocular Surface Staining Score | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | Damage of the ocular surface was measured by slit-lamp examination after staining with non-toxic fluorescein sodium. Corneal and conjunctival staining were graded as per the National Eye Institute (NEI) pictorial scale. The lower the score, the less signs of dry eye disease a patient exhibits. A negative change from baseline indicates an improvement in each eye. |
| Best Corrected Visual Acuity (BCVA) | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | Whether exosomes affect visual acuity. |
| Conjunctiva Redness Score | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | Conjunctival hyperemia was graded in each eye under slit-lamp magnification by assigning a score of 0 to 4 for each quadrant based on comparison to the Allergan Dry Eye Redness Scale with photographic reference where: 0=Normal, vessels of bulbar conjunctiva are easily observed; 1=Trace redness; 2=Mild redness; 3=Moderate redness; 4=Severe redness, and each score is associated with a reference photo. A negative change from baseline indicates an improvement in each eye. |
| Tear Secretion Test (Schirmer test) | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | A paper strip is placed on the eye under the lower lid for a specified time period. The length of the strip wetted by the tears was measured in millimeters. A positive change from baseline indicates an improvement in each eye. |
| Corneal confocal microscopy | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | The morphology, distribution and quantity of corneal nerve fibers were recorded by confocal image after LASIK and SMILE. |
| Meibomian gland expressibility scores | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | Squeeze the central meibomian glands of the lower eyelid and assess the expressibility of the five central glands, where 0= All glands have meibum extruded, 1= 3-4 glands have meibum extruded, 2=1-2 glands have meibum extruded, 3=no glands have meibum extruded. |
| Meibomian Glands Photography | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | The morphology, quantity and blockage of meibomian gland can be assigned a score of 0 to 3 points according to meibomian gland dropout, where 0=normal without dropout; 1=meibomian gland dropout\<1/3; 2=meibomian gland dropout 1/3-2/3; 3=meibomian gland dropout \>2/3. The total score of upper and lower meibomian glands is 6 points, of which Grade 0=0-1 point; Grade 1=2-3 points; Grade 2=4-5 points; Grade 3=6 points. |
| Tear Meniscus Height | 1 weeks, 2 weeks, 4 weeks, 8 weeks,12 weeks | The distance between the line of reflection along the top of the tear prism to the edge of the eyelid was measured in millimeters. A positive number change from baseline indicates improvement. |
Countries
China
Contacts
Primary ContactQi Gao, Doc.
Outcome results
None listed